Menu Back toBeyond Cancer: Why Pharma is Moving to High Quality Real-World Data for Immunology and Other Chronic Diseases

DIA 2021 Global Annual Meeting


Beyond Cancer: Why Pharma is Moving to High Quality Real-World Data for Immunology and Other Chronic Diseases

Session Chair(s)

Richard  Gliklich, MD

Richard Gliklich, MD

  • Chief Executive Officer
  • OM1, United States
Unlike cancer, there has been less focus on using real-world data (RWD) for autoimmune and other chronic conditions. This session explores the basics of what makes RWD high-quality and the uses for accelerating research and evaluating outcomes in these areas.
Learning Objective : Identify real-world data (RWD) utility in autoimmune conditions across research and development; Define data quality and what 'GCP' for RWD means; Apply data to personalize healthcare through artificial intelligence.

Speaker(s)

Xia  Wang, PhD

Industry Update

Xia Wang, PhD

  • Director, Health Informatics, Data Science and AI
  • AstraZeneca, United States
Christopher P Boone, PhD, MHA

Industry Update

Christopher P Boone, PhD, MHA

  • Vice President, Global Head, Health Economics and Outcomes Research
  • AbbVie, United States
Gary  Curhan, DrSc, MD

Industry Update

Gary Curhan, DrSc, MD

  • Chief Medical Officer
  • OM1, United States